CAS: 99-66-1; 2-Propylpentanoic Acid

上下游产品

CAS号1636-27-7 二丙基丙二酸 | CAS号13310-75-3 2-丙基戊腈 | CAS号76002-02-3 2,2-dipropyl-ac... | CAS号141-97-9 乙酰乙酸乙酯 | CAS号106-94-5 溴代丙烷 | CAS号17022-31-0 2-丙基戊酸乙酯 | CAS号22632-59-3 2-丙基戊酸甲酯 | CAS号1069-66-5 丙戊酸钠 | CAS号592-76-7 1-庚烯 | CAS号201230-82-2 carbon monoxide | CAS号22632-59-3 2-丙基戊酸甲酯 | CAS号2751-06-6 N-tert-butyl-2-... | CAS号2936-13-2 N-butyl-2-propy... | CAS号2653-58-9 1-morpholin-4-y... | CAS号2936-12-1 N-propan-2-yl-2... | CAS号2750-95-0 N-[2-(dimethyla... | CAS号2936-11-0 N,2-dipropylpen... | CAS号99174-91-1 2-溴-2-丙基戊酸乙酯 | CAS号58175-57-8 2-丙基-1-戊醇 | CAS号1069-66-5 丙戊酸钠

丙戊酰胺置于苯酐体系中,240.0~250.0 °C,405.3 Kpa 条件下,反应 0.75H,以92%的收率获得产物丙戊酸
参考文献:温和方便的酰胺"干式"水解为羧酸
标题:温和方便的酰胺"干式"水解为羧酸
摘要:描述了一种一锅法制备的羧酸,其在不存在水和溶剂的情况下通过与邻苯二甲酸酐的"干"水解从其相应的酰胺开始进行.该方法以非常好的产率提供了羧酸,并且适用于多种底物.
DOI:10.1016/s0040-4039(00)00507-4

专利信息

专利号:US-12383499-B2
优先权日:2018-01-01
标题:Scale up synthesis of silicasome nanocarriers
发明人：NEL ANDRE E; MENG HUAN; LIU XIANGSHENG
权利人:UNIV CALIFORNIA
摘要:In order to facilitate the approval and commercialization of silicasome drug delivery systems (e.g. irinotecan silicasomes) it is necessary to scale up synthesis of the drug-loaded silicasomes. In this regard, it was discovered that the synthesis protocols used for laboratory synthesis of drug-loaded silicasomes (e.g., 500 mg/batch) do not scale to large scale silicasome production, because the resulting products were too heterogeneous for use as pharmaceuticals. Accordingly, new methods are provided herein that effectively afford the large-scale production of mesoporous silica nanoparticles (MSNPs) and lipid bilayer coated MSNPs (silicasomes).

专利号:US-2012208232-A1
优先权日:2009-07-15
标 题:Cell-Free Synthesis of Active Reprogramming Transcription Factors
发明人：YANG WILLIAM; PATEL KEDAR; GHEBREMARIAM YOHANNES T; LEE JI EUN; WONG HANN-CHUNG; COOKE JOHN P; SWARTZ JAMES ROBERT
权利人:YANG WILLIAM; PATEL KEDAR; GHEBREMARIAM YOHANNES T; LEE JI EUN; WONG HANN-CHUNG; COOKE JOHN P; SWARTZ JAMES ROBERT
摘要:Compositions and methods are provided for the cell-free synthesis of active reprogramming factor polypeptides. The reprogramming factors may be synthesized as fusion proteins comprising a permeant domain, such as polyarginme. The cell free-synthesis may be conducted at about 25 C in a bacterial cell extract from genetically alterd cells having decreased endogenous protease activity Further, the proteins may comprise a fusion partner which enhances solubility and may be refolded on a column.

专利号:EP-0790982-B1
优先权日:1994-06-17
标 题 :Methods of synthesis of peptidyl argininals
发明人：WEBB THOMAS R; REINER JOHN E; TAMURA SUSAN Y; RIPKA WILLIAM C; DAGNINO RAYMOND JR; NUTT RUTH F
权利人:CORVAS INT INC
摘要:This invention provides solution-phase and solid-phase methods for the synthesis of peptidyl argininals and to novel reagents useful therein, which have formula (I), wherein R1 is selected from the group consisting of hydrogen, benzyloxycarbonyl, isonicotinyloxycarbonyl, 2-chlorobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, t-butoxycarbonyl, t-amyloxycarbonyl, isobornyloxycarbonyl, adamantyloxycarbonyl, 2-(4-biphenyl)-2-propyloxycarbonyl, 9-fluorenylmethoxycarbonyl and methylsulfonylethoxycarbonyl; R2 is selected from the group consisting of alkyl of 1 to about 12 carbon atoms and aralkyl of about 7 to about 15 carbon atoms, either of which is optionally substituted with hydroxy or -CO-Y, wherein Y is hydroxy, alkoxy of 1 to about 12 carbon atoms, aralkoxy of about 7 to about 15 carbon atoms, O-polymeric support or NH-polymeric support; R3 is selected from the group consisting of hydrogen, Fmoc, nitro, benzyloxycarbonyl, t-butoxycarbonyl and adamantyloxycarbonyl; and R4 is selected from the group consisting of hydrogen, alkyl of 1 to about 12 carbon atoms, aryl of about 6 to about 14 carbon atoms and aralkyl of about 7 to about 15 carbon atoms; and salts thereof.

专利号:US-2013302247-A1
优先权日:2012-05-09
标 题:Synthesis of fluoroarachidonic acid and methods of use thereof
发明人：PICHIKA RAMAIAH; ECKELMAN WILLIAM C; RAPOPORT STANLEY I; TAHA AMEER; KOTTA KISHORE
权利人:US HEALTH; UNIV CALIFORNIA
摘要:There are provided, inter alia, methods for diagnosis of the extent of neuroinflammation in a subject. The methods include administering an 18 F-labeled arachidonic acid to a subject in need thereof, obtaining a positron emission tomography (PET) scan of the subject, and determine the extent of neuroinflammation from the PET scan. There are provided, inter alia, methods of synthesis of reagents useful for the production of an 18 F-labeled arachidonic acid.

专利号:US-5731413-A
优先权日:1994-06-17
标 题:Method of synthesis of peptidyl aldehydes
发明人：WEBB THOMAS ROY; REINER JOHN EUGENE; TAMURA SUSAN YOSHIKO; RIPKA WILLIAM CHARLES; DAGNINO JR RAYMOND; NUTT RUTH FOELSCHE
权利人:CORVAS INT INC
摘要:This invention provides solution-phase and solid-phase methods for the synthesis of peptidyl argininals and to novel! reagents useful therein.

专利号:WO-2017100796-A1
优先权日:2015-12-11
标 题 :Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers
发明人：WONG CHI-HUEY; HSU TSUI-LING; WU CHUNG-YI; CHEUNG SARAH K C; CHUANG PO-KAI
权利人:SINACA ACAD; WONG CHI-HUEY; HSU TSUI-LING
摘要:The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta- 4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for disgnostic and therapeutic uses.